Valeant Pharmaceuticals International Inc. is preparing to namePaul Herendeen, an executive at veterinary drugmaker Zoetis Inc.,as its new chief financial officer, according to people familiarwith the matter.

The announcement will mark the latest management change at theembattled drugmaker, which replaced CEO Michael Pearson earlierthis year. Herendeen has been working as CFO at Zoetis since September 2014.Before that, he was CFO of specialty drugmaker Warner Chilcott Plc,according to Zoetis's website.

He replaces Robert Rosiello, who will remain at Valeant in anexecutive role involving corporate development and strategy,according to the people who spoke on condition of anonymity becausethe matter was still private. At Zoetis, Herendeen will be replacedby Glenn David, the company's senior vice president of financeoperations.

Complete your profile to continue reading and get FREE access to Treasury & Risk, part of your ALM digital membership.

  • Critical Treasury & Risk information including in-depth analysis of treasury and finance best practices, case studies with corporate innovators, informative newsletters, educational webcasts and videos, and resources from industry leaders.
  • Exclusive discounts on ALM and Treasury & Risk events.
  • Access to other award-winning ALM websites including and

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.